-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 26, the CDE official website showed that Hengrui's application for clinical trial of extracellular regulatory protein kinase (ERK) inhibitors has been approved by the State Food and Drug Administration by default.
The MAPK signaling pathway is transmitted to multiple targets in the cell via RAS-RAF-MEK-ERK.
Previously, BPI-27336 from Betta Pharmaceuticals, HH2710 jointly developed by the Chinese Academy of Sciences and Shanghai Haihe, and Hutchison Whampoa's HMPL-295S1 were approved for clinical use.
PharmaGo
In addition, Deck Pharmaceuticals reached a global exclusive license agreement with AstraZeneca in November 2019, and obtained the right to jointly develop and commercialize the ERK1/2 inhibitor AZD0364 (ATG-017).